Health news
A phase 3 study evaluating zuranolone in women with postpartum depression met its primary and key secondary endpoints, according to Sage Therapeutics and Biogen. Zuranolone is an investigational oral neuroactive steroid GABA-A receptor positive allosteric…
The Food and Drug Administration (FDA) has approved Igalmi (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi is an orally dissolving thin…
Use of a clinical decision support system was linked to significant reductions in cardiovascular disease risk among patients with schizophrenia, schizoaffective disorder, and bipolar disorder, according to research published in JAMA Network Open. The system…
A large database study examining more than 2.5 million patients found people with schizophrenia were nearly 4 times more likely to die from COVID-19 than the general population. People with mood disorders were more than…
The Food and Drug Administration (FDA) has approved Caplyta (lumateperone) for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.…
Racial and ethnic disparities exist in patients with depression, according to a recent retrospective analysis published in the Lancet Psychiatry. The authors believe the study is among the first to show patient preference for culturally…
While cultural attitudes toward animals may vary, researchers note there is a “commonly held belief that pets can improve the overall quality of human life.”1 In fact, there appears to be growing recognition of the…
Lybalvi® (olanzapine and samidorphan) is now available for the treatment of schizophrenia in adults and for bipolar I disorder in adults for acute treatment of manic or mixed episodes as monotherapy and as an adjunct…
The Food and Drug Administration (FDA) has cleared BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) system for the reduction of comorbid anxiety symptoms in adult patients with depression, expanding the indication beyond treatment of depressive…
The Food and Drug Administration (FDA) has cleared BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) system for the reduction of comorbid anxiety symptoms in adult patients with depression, expanding the indication beyond treatment of depressive…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021